Notes on Rapid Pathogen Detection, Antibiotic Susceptibility Testing, and 3D Bladder Cancer Invasion with Biosensor Technologies
Pathogen detection and rapid antibiotic susceptibility testing
Project aim: develop rapid, high-throughput methods to detect pathogens (e.g., E. coli, Pseudomonas aeruginosa) and to screen antibiotic sensitivity, reducing traditional timelines from days to hours.
Field of application: rapid pathogen identification and antibiotic susceptibility testing in patient samples; also demonstrates high-throughput screening capability.
System overview (first project): a microfluidic/biosensor workflow that can screen bacteria and identify pathogens using color-coded signals.
Color coding in figures:
Red signals for E. coli
Green signals for other targets (e.g., Pseudomonas aeruginosa, PA)
Core sensing strategy: use a carbon nanotube (CNT)–based probe where a strand complementary to a bacterial gene is bound to the CNT; a fluorophore is quenched in the absence of target RNA and becomes fluorescent when the target is present.
Probe design details:
One strand is complementary to a gene in the bacteria.
CNTs facilitate cellular entry (via electroporation or related uptake mechanism).
In the absence of target RNA, the fluorophore is quenched by the CNT; upon binding to the target, the signal is unquenched/released.
Two-color system allows discrimination between E. coli and PA within the same assay.
Dynamic behavior: shorter probe strand yields relatively higher free energy, enabling selective interaction with E. coli under the conditions tested.
Visualization: time-lapse video demonstrates live movement of bacteria, indicating viability during testing.
Throughput and time gains:
Traditional timelines can extend to roughly
for standard pathogen identification and susceptibility testing.The project aims to reduce this to roughly
or so, dramatically shortening the window to targeted therapy.
Sensitivity and counting: the presence of bacteria at very low counts can still be identified with the CNT-based biosensor, enabling fast, low-sample-detection capabilities.
Antibiotic susceptibility testing (AST) workflow:
Patient samples that test positive for E. coli are loaded into microtubes with the biosensor system.
After loading, a short incubation (e.g., ) precedes antibiotic exposure.
Antibiotics are applied and growth is monitored; resistant strains show growth while susceptible strains do not.
Example reference from the transcript: in one comparison, after antibiotic application, only a single sample showed growth (a marker of resistance) while others did not.
Size-based separation for unknown clinical samples:
Separation method leverages physical size differences to classify bacteria.
Process: bacteria are placed in a microfluidic channel (or macro “stool” sample) and subjected to controlled pressure.
Large bacteria are trapped at low pressure; smaller bacteria require higher pressure to be trapped.
Resulting rearranged images allow categorization by shape: cocci (spherical) vs. bacilli (rod-shaped).
Patient data and outcomes (summary):
Across 25 patient samples analyzed, a subset was identified as resistant to the tested antibiotic, highlighting the system’s potential for rapid resistance profiling.
The approach demonstrates both rapid pathogen detection and high-throughput antibiotic screening using the same platform.
Key implications:
Potential to shorten the time to targeted therapy, reduce misuse of broad-spectrum antibiotics, and enable rapid, personalized antibiotic stewardship.
The method integrates pathogen detection with functional AST in a single workflow, which could transform clinical decision-making in infectious disease management.
Bladder cancer invasion studies and 3D tumor microenvironment modeling
Primary clinical focus: bladder cancer, with two major disease states discussed:
Non-muscle invasive bladder cancer (NMIBC): high recurrence; intravesical therapy with BCG (Bacillus Calmette–Guérin) bacteria to stimulate local immune response and attack cancer cells.
Muscle-invasive bladder cancer (MIBC): higher risk of metastasis; about ~50% recurrence; standard treatment includes cystectomy (removal of the bladder), chemotherapy, immune-modulating strategies, and other adjuvants.
3D tumor microenvironment model:
Matrix and scaffold: collagen and Matrigel are used to mimic the basement membrane and extracellular matrix (ECM) encountered by bladder cancer cells in vivo.
Culture setup: cancer cells are cultured on top of the Matrigel/collagen scaffold to form a macroscopic tumor structure in a 3D context.
Observations:
Cells embedded within the collagen matrix (green fluorescence/labels) gradually migrate and invade deeper into the matrix; co-culture conditions influence invasion compared to single-cell cultures.
The green fraction represents cells embedded within the collagen; as invasion proceeds, the macro-tumor forms and expands in 3D.
Tumor microenvironment and immune interaction goals:
Study intratumor and intertumor heterogeneity in invasion and response to therapies.
Investigate how immune cells interact with tumors and respond to microbial (BCG) treatments within a realistic 3D context.
Use the 3D model to probe how BCG (and other immunotherapies) modulate invasion and immune cell activity.
Notch/Dll4 signaling and leader cells in collective invasion:
Notch signaling pathway and Delta-like ligand 4 (Dll4) signaling are implicated in regulating collective tumor invasion and the formation of leader cells during invasion.
The project aims to understand how Notch-Dll4 signaling influences the behavior of leader cells and the overall invasion pattern in the 3D co-culture system.
Gold nanorod RNA probes (GNR RNA probes) for intratumoral mRNA detection:
Probe design: gold nanorods (GNRs) conjugated with an RNA probe that has fluorophores at both ends (5' and 3'). The target mRNA inside cancer cells triggers fluorescence release.
Mechanism: the GNR quenches fluorescence until hybridization with target mRNA occurs; upon binding, fluorescence is emitted, providing a readout of target mRNA presence.
Uptake: GNR probes are taken up spontaneously by cells without transfection reagents.
Readout: fluorescence (red for overall cancer cells; green signal indicates probe activation) can be observed under a fluorescence microscope; the method supports both 2D and 3D assays.
Applications demonstrated:
Mapping invasive behavior in patient-derived cells within the 3D model.
Assessing the efficacy of chemotherapeutic drugs and other compounds in reducing invasion or altering gene expression patterns.
Applications to drug testing and personalized therapy:
The 3D co-culture platform enables testing of how chemo drugs or other agents affect invasion and tumor morphology in a patient-specific context.
The system allows evaluation of how different treatments influence collective tumor invasion and leader cell dynamics.
Cytotoxic T cells, immunotherapy, and biosensor-assisted selection:
Background: Current immunotherapies include expanding tumor-infiltrating lymphocytes (TILs) ex vivo to generate cytotoxic T cells that recognize tumor antigens.
Objective: Improve adoptive T cell therapy by selectively enriching cytotoxic T cells using a biosensor-based approach that detects markers indicating cytotoxic function.
Practical goal: Use the biosensor to select higher-quality T cells for patient therapies, potentially improving efficacy and reducing off-target effects.
Notable context: A related immunotherapy approach uses tumor-infiltrating T cells; the biosensor aims to enhance selection and expansion of cytotoxic populations.
BCG immunotherapy and macro-immune integration in bladder cancer:
BCG is used as a localized immune stimulant in NMIBC; understanding its interaction with the tumor and immune microenvironment is a goal of the 3D model studies.
Experimental and analytical outcomes:
The integrated 3D model (collagen/Matrigel) provides a more physiologically relevant framework to study invasion, immune interactions, and drug responses than traditional 2D cultures.
GNR-based probes offer a noninvasive readout of target mRNA dynamics within living cells, enabling real-time assessment of invasion-related signaling and treatment effects in 3D contexts.
The Notch-Dll4 signaling axis and its role in leader cell formation offer mechanistic insight into how collective invasion is coordinated in the bladder cancer model.
Connections to broader principles and potential real-world relevance:
The work exemplifies the shift from 2D to 3D tumor models for more faithful representation of tumor biology and therapeutic responses.
The combination of nanomaterials (gold nanorods) with RNA-based probes showcases a nonviral, fluorescence-based readout mechanism for intracellular targets.
Insights into leader cells and signaling pathways (Notch/Dll4) can inform strategies to disrupt invasive fronts and metastasis.
The immunotherapy angle emphasizes the importance of selecting optimal T cell populations for adoptive therapy, potentially improving patient outcomes.
Ethical, practical, and translational considerations:
Safety and regulatory considerations for clinical use of nanomaterials and CNT-based probes in human samples.
Biosafety concerns with using live bacteria (BCG) in intravesical therapy and the need to balance immune activation with potential adverse events.
Translational relevance hinges on validating 3D model findings in patient trials and ensuring scalability of the biosensor platform for clinical workflows.
Summary of the two-pronged research aim:
Develop rapid, high-throughput pathogen detection and antibiotic susceptibility testing to guide timely clinical decisions.
Build a sophisticated 3D bladder cancer invasion model incorporating Notch signaling and GNR RNA probes to study invasion, drug response, and immunotherapeutic optimization (including cytotoxic T cell selection), with potential extensions to single-cell analyses.
Key takeaways and synthetic connections
The pathogen detection system demonstrates how nanomaterial-based probes can dramatically shorten diagnostic timelines and enable simultaneous multi-pathogen detection and antibiotic screening.
The bladder cancer invasion studies highlight the value of 3D microenvironments to capture realistic tumor-immune-drug interactions and the potential of nanomaterial–RNA probes for intracellular sensing within a native-like tissue context.
Across both projects, the integration of advanced materials (carbon nanotubes, gold nanorods), microfabrication/3D culture systems, and signaling pathway analysis (Notch/Dll4) exemplifies a modern, multi-disciplinary approach to translational biomedicine.
The overarching clinical rationale centers on enhancing diagnostic speed, personalizing therapy, and enabling mechanistic understanding of invasion and immune interactions to inform better treatments.